Upadacitinib in Crohn's disease

A Dignass, P Esters, C Flauaus - Expert Opinion on …, 2024 - Taylor & Francis
Introduction The small molecule and oral selective and reversible Janus kinase (JAK)
inhibitor upadacitinib has been approved for the treatment of moderate to severe active …

Treatment strategies in inflammatory bowel diseases

A Stallmach, R Atreya, PC Grunert… - Deutsches …, 2023 - pmc.ncbi.nlm.nih.gov
Background The prevalence of inflammatory bowel disease (IBD) is rising globally. In
Germany, these conditions affect 0.7% of the population, or approximately 600 000 patients …

Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn's Disease and Ulcerative Colitis Compared With Healthy Control Individuals

HC Tews, F Schmelter, A Kandulski… - Inflammatory Bowel …, 2024 - academic.oup.com
Background Accurate biomarkers for disease activity and progression in patients with
inflammatory bowel disease (IBD) are a prerequisite for individual disease characterization …

Prioritization in inflammatory bowel disease therapy

KR Herrlinger, EF Stange - Expert Review of Gastroenterology & …, 2023 - Taylor & Francis
Introduction Most guidelines for IBD still recommend step-by-step therapy with initially
classic drugs such aminosalicylates (in ulcerative colitis) or steroids but avoid prioritizing …

Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD …

B Bokemeyer, S Plachta-Danielzik… - Inflammatory Bowel …, 2024 - academic.oup.com
Background The aim of this observational, real-world evidence, modified intention-to-treat
(mITT) study based on prospectively collected data from the VEDOIBD registry was to …

To STRIDE or not to STRIDE: A critique of “treat to target” in Crohn s disease

KR Herrlinger, EF Stange - Expert Review of Gastroenterology & …, 2023 - Taylor & Francis
Introduction The STRIDE consensus suggested to focus on mucosal healing, based on
biomarkers and endoscopy, in addition to clinical endpoints as treatment target. This …

Real‐world effectiveness of vedolizumab compared to anti‐TNF agents in biologic‐naïve patients with ulcerative colitis: a two‐year propensity‐score‐adjusted …

B Bokemeyer, S Plachta‐Danielzik… - Alimentary …, 2023 - Wiley Online Library
Background This observational real‐world evidence (RWE) study is based on prospectively
collected data from the VEDOIBD registry study. Aim To compare the effectiveness of …

Mind-body-medicine and comprehensive lifestyle-modification in patients with Crohn's disease—Feasibility of a randomized controlled trial under pandemic …

N Bauer, C Löffler, Ö Öznur, C Uecker, T Keil… - Frontiers in Integrative …, 2022 - frontiersin.org
Introduction Mind-body medicine (MBM) focuses on stress reduction and lifestyle changes.
The primary objective of this pilot trial was to test study feasibility of a complex integrative …

Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised …

B Bokemeyer, S Plachta‐Danielzik… - Alimentary …, 2024 - Wiley Online Library
Background IBDBIO‐ASSIST was a randomised controlled trial assessing the efficacy of
care provided by IBD nurse specialists in Germany in improving health‐related quality of life …

[HTML][HTML] Pro-inflammatory NK-like T cells are expanded in the blood and inflamed intestine in Crohn's disease

CM Chiarolla, AR Schulz, M Meir, S Ferrara, Y **ao… - Mucosal …, 2024 - Elsevier
Altered intestinal immune homeostasis leads to chronic inflammation in Crohn's disease
(CD). To address disease-and tissue-specific alterations, we performed a T cell-centric mass …